{
  "research_data": {
    "session_id": "cancer_immuno_002",
    "created_at": "2025-01-12T14:15:00Z",
    "research_focus": "Novel cancer immunotherapy approaches"
  },
  "generated_hypotheses": [
    {
      "hypothesis_id": "car_t_001",
      "research_question": "Can engineered CAR-T cells overcome solid tumor resistance?",
      "hypothesis_text": "Fourth-generation CAR-T cells engineered with IL-12 secretion and PD-1 knockout can overcome the immunosuppressive tumor microenvironment in solid tumors, leading to sustained anti-tumor responses",
      "biological_domain": "cancer_immunotherapy",
      "tumor_type": "solid_tumors",
      "approach": "car_t_engineering",
      "novelty_score": 0.9,
      "feasibility_score": 0.7,
      "supporting_evidence": [
        "IL-12 enhances T-cell activation and persistence",
        "PD-1 knockout prevents T-cell exhaustion",
        "Armored CAR-T cells show improved efficacy in preclinical models"
      ]
    },
    {
      "hypothesis_id": "checkpoint_002", 
      "research_question": "What combination therapies can enhance checkpoint inhibitor efficacy?",
      "hypothesis_text": "Combining anti-PD-1 therapy with STING agonists and tumor-associated antigen vaccines can create a synergistic immune response that overcomes checkpoint inhibitor resistance in melanoma",
      "biological_domain": "cancer_immunotherapy",
      "tumor_type": "melanoma",
      "approach": "combination_therapy",
      "novelty_score": 0.8,
      "feasibility_score": 0.85,
      "supporting_evidence": [
        "STING activation enhances dendritic cell function",
        "Vaccines can broaden T-cell repertoire",
        "Combination approaches show promise in clinical trials"
      ]
    }
  ],
  "analysis_metadata": {
    "total_generated": 2,
    "avg_novelty_score": 0.85,
    "avg_feasibility_score": 0.775,
    "research_categories": ["immunotherapy", "cancer_biology", "translational_medicine"],
    "verification_status": "pending_biomni"
  }
}
